Your browser is no longer supported. Please, upgrade your browser.
RLAY Relay Therapeutics, Inc. daily Stock Chart
Relay Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own3.00% Shs Outstand83.21M Perf Week-3.94%
Market Cap3.39B Forward P/E- EPS next Y-1.67 Insider Trans0.00% Shs Float45.84M Perf Month-7.87%
Income- PEG- EPS next Q-0.34 Inst Own24.10% Short Float11.11% Perf Quarter-1.36%
Sales- P/S- EPS this Y-54.40% Inst Trans- Short Ratio12.40 Perf Half Y-
Book/sh- P/B- EPS next Y21.20% ROA- Target Price49.33 Perf Year-
Cash/sh3.75 P/C10.85 EPS next 5Y- ROE- 52W Range32.56 - 49.89 Perf YTD16.18%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-21.85% Beta-
Dividend %- Quick Ratio24.70 Sales past 5Y- Gross Margin- 52W Low19.75% ATR3.52
Employees123 Current Ratio24.70 Sales Q/Q- Oper. Margin- RSI (14)46.13 Volatility8.58% 9.35%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.50 Prev Close40.72
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume410.81K Price38.99
Recom2.00 SMA20-5.82% SMA50-0.60% SMA2000.47% Volume205,061 Change-4.25%
Aug-10-20Initiated JP Morgan Neutral $36
Aug-10-20Initiated Guggenheim Buy $48
Aug-10-20Initiated Goldman Buy $64
Aug-10-20Initiated Cowen Outperform
Oct-16-20 10:53AM  
Sep-03-20 04:05PM  
Aug-27-20 06:50AM  
Aug-16-20 08:59AM  
Aug-11-20 06:40AM  
Aug-06-20 06:07PM  
Jul-20-20 04:05PM  
Jul-17-20 04:17PM  
Jul-16-20 04:28PM  
Jul-15-20 08:51PM  
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.